Clinical trial
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
NCT00195819 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00195819 |
|---|---|
| Title | Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis |
| Official title | A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ankylosing Spondylitis |
| Intervention type | Biological |
| Interventions | adalimumab (D2E7), placebo |
| Enrollment | 82 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Jun 1, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Jun 28, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: